Your email has been successfully added to our mailing list.

×
0.000374812593703207 0.000374812593703207 0.00112443778110949 0.00112443778110949 0.00243628185907051 0.00299850074962526 0.000749625187406414 0.000749625187406414
Stock impact report

Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful [CNBC]

Merck & Company, Inc. (new) (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
Company Research Source: CNBC
The future of cancer immunotherapy looks promising, but it suffered a major setback on Friday. Incyte announced that its trial drug epacadostat did not help melanoma patients, and the company is halting the study altogether. Epacadostat was supposed to work in conjunction with Merck's blockbuster cancer immunotherapy drug Keytruda — which has delivered billions in revenue to the pharmaceutical giant — to help the immune system fight cancer. The immune system contains T cells. These cells know the difference between a normal cell they should leave alone and a foreign cell they should attack. The problem is many cancer cells also look normal to T cells. Keytruda helps T cells recognize and fight cancer cells. Drugs like Keytruda are called checkpoint inhibitors. Epacadostat was supposed to further immunotherapy. The body contains an enzyme called IDO , which stops T cells from doing their job. Epacadostat is an IDO inhibitor, meaning it stops IDO from suppressing T Show less Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
MRK alerts

from News Quantified
Opt-in for
MRK alerts

from News Quantified